TY - JOUR AU - Sun, C. C. AU - Bodurka, D. C. AU - Weaver, C. B. PY - 2005 DA - 2005// TI - Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer JO - Support Care Cancer VL - 13 UR - https://doi.org/10.1007/s00520-004-0710-6 DO - 10.1007/s00520-004-0710-6 ID - Sun2005 ER - TY - JOUR AU - Bloechl-Daum, B. AU - Deuson, R. R. AU - Mavros, P. PY - 2006 DA - 2006// TI - Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.05.6382 DO - 10.1200/JCO.2006.05.6382 ID - Bloechl-Daum2006 ER - TY - JOUR AU - Lorusso, V. AU - Spedicato, A. AU - Petrucelli, L. PY - 2009 DA - 2009// TI - Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC) JO - Preliminary results Support Care Cancer VL - 17 UR - https://doi.org/10.1007/s00520-009-0611-9 DO - 10.1007/s00520-009-0611-9 ID - Lorusso2009 ER - TY - STD TI - Gralla RJ, Roila F, Tonato M, et al. Title of subordinate document. In: MASCC/ESMO antiemetic guideline. In: Multinational Association of Supportive Care in Cancer; 2013. http://www.mascc.org/assets/Guidelines-Tools/mascc_guidlines_english_2014.pdf. Accessed Dec 2014. UR - http://www.mascc.org/assets/Guidelines-Tools/mascc_guidlines_english_2014.pdf ID - ref4 ER - TY - JOUR AU - Basch, E. AU - Prestrud, A. A. AU - Hesketh, P. J. PY - 2011 DA - 2011// TI - Antiemetics: American Society of Clinical Oncology clinical practice guideline update JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.34.4614 DO - 10.1200/JCO.2010.34.4614 ID - Basch2011 ER - TY - CHAP AU - Ettinger, D. S. AU - Berger, M. J. AU - Armstrong, D. K. PY - 2014 DA - 2014// TI - Title of subordinate document. In: NCCN version 2 BT - Antiemesis National Comprehensive Cancer Network ID - Ettinger2014 ER - TY - CHAP PY - 2015 DA - 2015// BT - JSCO Clinical Practice Guideline PB - Co., Ltd CY - Tokyo, Japan ID - ref7 ER - TY - JOUR AU - Chawa, S. P. AU - Grunberg, S. M. AU - Gralla, R. J. PY - 2013 DA - 2013// TI - Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting JO - Cancer VL - 97 UR - https://doi.org/10.1002/cncr.11320 DO - 10.1002/cncr.11320 ID - Chawa2013 ER - TY - JOUR AU - Nishimura, J. AU - Satoh, T. AU - Fukunaga, M. PY - 2015 DA - 2015// TI - Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.03.024 DO - 10.1016/j.ejca.2015.03.024 ID - Nishimura2015 ER - TY - JOUR AU - Aapro, M. S. PY - 2007 DA - 2007// TI - Palonosetron as an anti-emetic and anti-nausea agent in oncology JO - Ther Clin Risk Manag VL - 3 ID - Aapro2007 ER - TY - JOUR AU - Oken, M. M. AU - Creech, R. H. AU - Tormey, D. C. PY - 1982 DA - 1982// TI - Toxicity and response criteria of the eastern cooperative oncology group JO - Am J Oncol VL - 5 UR - https://doi.org/10.1097/00000421-198212000-00014 DO - 10.1097/00000421-198212000-00014 ID - Oken1982 ER - TY - STD TI - National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. 2009. http://evs.nci.nih.gov/ftp1/CTCAE/About.html. UR - http://evs.nci.nih.gov/ftp1/CTCAE/About.html ID - ref12 ER - TY - JOUR AU - Cutsem, E. AU - Rivera, F. AU - Berry, S. PY - 2009 DA - 2009// TI - Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study JO - Ann Oncol VL - 20 ID - Cutsem2009 ER - TY - JOUR AU - Cassidy, J. AU - Clarke, S. AU - Díaz-Rubio, E. PY - 2008 DA - 2008// TI - Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.14.9898 DO - 10.1200/JCO.2007.14.9898 ID - Cassidy2008 ER - TY - JOUR AU - Yamada, Y. AU - Tahara, M. AU - Miya, T. PY - 2008 DA - 2008// TI - Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer JO - Br J Cancer VL - 98 UR - https://doi.org/10.1038/sj.bjc.6604271 DO - 10.1038/sj.bjc.6604271 ID - Yamada2008 ER - TY - JOUR AU - Muro, K. AU - Boku, N. AU - Shimada, Y. PY - 2010 DA - 2010// TI - Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(10)70181-9 DO - 10.1016/S1470-2045(10)70181-9 ID - Muro2010 ER - TY - JOUR AU - Komiyama, S. AU - Katabuchi, H. AU - Mikami, M. PY - 2016 DA - 2016// TI - Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer JO - Int J Clin Oncol VL - 21 UR - https://doi.org/10.1007/s10147-016-0985-x DO - 10.1007/s10147-016-0985-x ID - Komiyama2016 ER - TY - JOUR AU - Wang, F. AU - Mishina, S. AU - Takai, S. PY - 2017 DA - 2017// TI - Systemic treatment patterns with advanced or recurrent non-small cell lung Cancer in Japan: a retrospective hospital administrative database study JO - Clin Ther VL - 39 UR - https://doi.org/10.1016/j.clinthera.2017.04.010 DO - 10.1016/j.clinthera.2017.04.010 ID - Wang2017 ER - TY - JOUR AU - Rubin, D. B. PY - 1997 DA - 1997// TI - Estimating causal effects from large data sets using propensity scores JO - Ann Intern Med VL - 127 UR - https://doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00064 DO - 10.7326/0003-4819-127-8_Part_2-199710151-00064 ID - Rubin1997 ER - TY - JOUR AU - Katayama, M. AU - Inui, N. AU - Tanaka, K. PY - 2018 DA - 2018// TI - Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis JO - Med Oncol VL - 35 UR - https://doi.org/10.1007/s12032-018-1199-z DO - 10.1007/s12032-018-1199-z ID - Katayama2018 ER - TY - JOUR AU - Hesketh, P. J. AU - Grunberg, S. M. AU - Gralla, R. J. PY - 2003 DA - 2003// TI - The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant protocol 052 study group JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.01.095 DO - 10.1200/JCO.2003.01.095 ID - Hesketh2003 ER - TY - JOUR AU - Poli-Bigelli, S. AU - Rodrigues-Pereira, J. AU - Carides, A. D. PY - 2003 DA - 2003// TI - Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America JO - Cancer VL - 97 UR - https://doi.org/10.1002/cncr.11433 DO - 10.1002/cncr.11433 ID - Poli-Bigelli2003 ER - TY - JOUR AU - Warr, D. G. AU - Hesketh, P. J. AU - Gralla, R. J. PY - 2005 DA - 2005// TI - Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.09.050 DO - 10.1200/JCO.2005.09.050 ID - Warr2005 ER - TY - JOUR AU - Takahashi, T. AU - Hoshi, E. AU - Takagi, M. PY - 2010 DA - 2010// TI - Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin JO - Cancer Sci VL - 101 UR - https://doi.org/10.1111/j.1349-7006.2010.01689.x DO - 10.1111/j.1349-7006.2010.01689.x ID - Takahashi2010 ER - TY - JOUR AU - Suzuki, K. AU - Yamanaka, T. AU - Hashimoto, H. PY - 2016 DA - 2016// TI - Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw220 DO - 10.1093/annonc/mdw220 ID - Suzuki2016 ER - TY - JOUR AU - Longo, F. AU - Mansueto, G. AU - Lapadula, V. PY - 2012 DA - 2012// TI - Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy JO - Int J Clin Pract VL - 66 UR - https://doi.org/10.1111/j.1742-1241.2012.02969.x DO - 10.1111/j.1742-1241.2012.02969.x ID - Longo2012 ER - TY - JOUR AU - Toda, H. AU - Kawazoe, H. AU - Yano, A. PY - 2017 DA - 2017// TI - Antiemetic effectiveness and cost-saving of Aprepitant plus Granisetron is superior to Palonosetron in gastrointestinal Cancer patients who received moderately Emetogenic chemotherapy JO - J Cancer VL - 8 UR - https://doi.org/10.7150/jca.17102 DO - 10.7150/jca.17102 ID - Toda2017 ER - TY - JOUR AU - Kitayama, H. AU - Tsuji, Y. AU - Sugiyama, J. PY - 2015 DA - 2015// TI - Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study JO - Int J Clin Oncol VL - 20 UR - https://doi.org/10.1007/s10147-015-0823-6 DO - 10.1007/s10147-015-0823-6 ID - Kitayama2015 ER - TY - JOUR AU - Fujiwara, S. AU - Terai, Y. AU - Tsunetoh, S. PY - 2015 DA - 2015// TI - Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer JO - J Gynecol Oncol VL - 26 UR - https://doi.org/10.3802/jgo.2015.26.4.311 DO - 10.3802/jgo.2015.26.4.311 ID - Fujiwara2015 ER - TY - JOUR AU - Komatsu, Y. AU - Okita, K. AU - Yki, S. PY - 2015 DA - 2015// TI - Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron JO - Cancer Sci VL - 106 UR - https://doi.org/10.1111/cas.12675 DO - 10.1111/cas.12675 ID - Komatsu2015 ER - TY - JOUR AU - Mehra, N. AU - Ganesan, P. AU - Ganesan, T. S. PY - 2017 DA - 2017// TI - Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy JO - Med Oncol VL - 35 UR - https://doi.org/10.1007/s12032-017-1074-3 DO - 10.1007/s12032-017-1074-3 ID - Mehra2017 ER - TY - JOUR AU - Sekine, I. AU - Segawa, Y. AU - Kubota, K. PY - 2013 DA - 2013// TI - Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis JO - Cancer Sci VL - 104 UR - https://doi.org/10.1111/cas.12146 DO - 10.1111/cas.12146 ID - Sekine2013 ER - TY - JOUR AU - Osoba, D. AU - Zee, B. AU - Pater, J. AU - Warr, D. PY - 1997 DA - 1997// TI - Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of life and symptom control committees of the National Cancer Institute of Canada clinical trials group JO - J Clin Oncol VL - 15 UR - https://doi.org/10.1200/JCO.1997.15.1.116 DO - 10.1200/JCO.1997.15.1.116 ID - Osoba1997 ER - TY - JOUR AU - Hesketh, P. AU - Navari, R. AU - Grote, T. PY - 1996 DA - 1996// TI - Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron comparative chemotherapy-induced Emesis prevention group JO - J Clin Oncol VL - 14 UR - https://doi.org/10.1200/JCO.1996.14.8.2242 DO - 10.1200/JCO.1996.14.8.2242 ID - Hesketh1996 ER - TY - JOUR AU - Warr, D. PY - 2014 DA - 2014// TI - Prognostic factors for chemotherapy induced nausea and vomiting JO - Eur J Pharmacol VL - 5 UR - https://doi.org/10.1016/j.ejphar.2013.10.015 DO - 10.1016/j.ejphar.2013.10.015 ID - Warr2014 ER - TY - JOUR AU - Pollera, C. F. AU - Giannarelli, D. PY - 1989 DA - 1989// TI - Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model JO - Cancer VL - 64 UR - https://doi.org/3.0.CO;2-R DO - 3.0.CO;2-R ID - Pollera1989 ER - TY - JOUR AU - Tsuji, Y. AU - Baba, H. AU - Takeda, K. PY - 2017 DA - 2017// TI - Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan JO - Expert Opin Pharmacother VL - 18 UR - https://doi.org/10.1080/14656566.2017.1317746 DO - 10.1080/14656566.2017.1317746 ID - Tsuji2017 ER - TY - STD TI - Tsuji D, Suzuki K, Kawasaki Y, et al. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer. 2018. https://doi.org/10.1007/s00520-018-4403-y. Epub ahead of print. ID - ref38 ER - TY - JOUR AU - Puri, S. AU - Hyland, K. A. AU - Weiss, K. C. PY - 2018 DA - 2018// TI - Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors JO - Support Care Cancer VL - 26 UR - https://doi.org/10.1007/s00520-018-4120-6 DO - 10.1007/s00520-018-4120-6 ID - Puri2018 ER -